Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Senesco Technologies has submitted an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its lead drug candidate SNS01-T for treatment of multiple myeloma.
Subscribe to our email newsletter
Senesco was previously granted orphan drug status for SNS01-T.
Senesco plans to evaluate SNS01-T in patients with relapsed or refractory disease who have failed at least two standard treatment regimens.
Senesco president and CEO Leslie Browne said their first IND submission is a significant milestone for Senesco.
"It is designed to regulate what we believe is an important growth control switch that induces programmed cell death, also known as apoptosis," Browne said.
"If this therapeutic approach is successful, we believe it has the potential to change the progression of the disease and significantly impact patients’ lives."